BioPharm America EBD Group Massachusetts Biotechnology Council BioPharm America
Share:
Email this page Share this on LinkedIn Share this on Twitter

Videos


Social media in the life sciences with Steve Dickman of CBT Advisors Social media in the life sciences with Steve Dickman of CBT AdvisorsSeptember 18, 2013 | BioPharm America™ 2013Steve Dickman, CEO of CBT Advisors, recaps the BioPharm America 2013 panel discussion on social media in the life sciences, which featured fellow active users in the space. View session here View session here
A new era: Melding of drugs, devices and information A new era: Melding of drugs, devices and informationSeptember 17, 2013 | BioPharm America™ 2013This discussion focuses on the use of technology to enhance the clinical and holistic well-being of individual patients, especially the geriatric population. View session here View session here
Academic Innovators™ Showcase at BioPharm America Academic Innovators™ Showcase at BioPharm AmericaSeptember 19, 2013 | BioPharm America™ 2013This year at BioPharm America we launched our inaugural Academic Innovators Showcase to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world. View session here View session here
Executive Interview with Robert Urban Executive Interview with Robert UrbanSeptember 17, 2013 | BioPharm America™ 2013Robert Urban discusses how J&J's new Boston Innovation Center is a focal point for the company's engagement with early stage innovation. View session here View session here
Executive Interview with Jens Eckstein Executive Interview with Jens EcksteinSeptember 18, 2013 | BioPharm America™ 2013The new approach to VC investing promises to move more companies to the winners circle and ultimately make drug portfolios stronger. View session here View session here
Early stage development: At the intersection of academic, biotech and pharma Early stage development: At the intersection of academic, biotech and pharmaSeptember 17, 2013 | BioPharm America™ 2013Pharma and academia are collaborating to fill drug pipelines. Can they overcome key differences to make it work? Robin Wright interviews Erik Halvorsen at BioPharm America. View session here View session here
Leveraging big data to discover and develop breakthrough treatments Leveraging big data to discover and develop breakthrough treatmentsSeptember 17, 2013 | BioPharm America™ 2013Big data is big news, but how can it be leveraged to discover and develop breakthrough treatments? Iya Khalil interviews Stanley Shaw about big data’s meaningful application. View session here View session here
Who will be funding early stage biotech in the future? Who will be funding early stage biotech in the future?September 18, 2013 | BioPharm America™ 2013Luke Timmerman of Xconomy engages VCs on the outlook for future early stage investing and the pool of potential investors. View session here View session here
Personalized medicine: The path to broader adoption Personalized medicine: The path to broader adoptionSeptember 17, 2013 | BioPharm America™ 2013What can we learn from the rare genetic disorder space and orphan drug space which are pioneering areas of personalized medicine? What R&D models will be necessary? View session here View session here
Interview with Garry Neil on TransCelerate BioPharma Interview with Garry Neil on TransCelerate BioPharmaSeptember 20, 2012 | BioPharm America™ 2012Garry Neil explains the impetus behind and goals of TransCelerate BioPharma, a new nonprofit organization focused on accelerating the development of new medicines. View session here View session here
Interview with David de Graaf of Selventa Interview with David de Graaf of SelventaSeptember 20, 2012 | BioPharm America™ 2012David de Graaf of Selventa is pioneering the development of a new class of innovative "Systems Diagnostics" for personalized medicine. View session here View session here
Interview with John Brooks, Joslin Diabetes Center Interview with John Brooks, Joslin Diabetes CenterSeptember 20, 2012 | BioPharm America™ 2012John Brooks is positioning the Joslin Diabetes Center as the hub of innovation and research partnerships in diabetes. View session here View session here
Interview Jason Rhodes of Epizyme Interview Jason Rhodes of EpizymeSeptember 20, 2012 | BioPharm America™ 2012Epizyme is aiming to create personalized therapeutics for patients with genetically-defined cancers using a branch of epigenetics called histone methyltransferases (HMTs) View session here View session here
Interview with Kevin Krenitsky of Foundation Medicine Interview with Kevin Krenitsky of Foundation MedicineSeptember 20, 2012 | BioPharm America™ 2012Foundation Medicine is blazing new trails in personalized medicine for cancer patients. View session here View session here
From start-up to commercial company and the challenges in between: Could we do it again today? From start-up to commercial company and the challenges in between: Could we do it again today?September 20, 2012 | BioPharm America™ 2012Karen Bernstein of BioCentury leads a discussion of the challenges in taking a company from start-up to commercial success. How is this different today than in years past? View session here View session here
Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it? Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it?September 20, 2012 | BioPharm America™ 2012Diabetes continues, despite major treatment advances, to warrant new, novel therapies to further help patients gain better control of their disease. How are we doing? View session here View session here
Best deal structures: How do you operationalize external R&D?   Best deal structures: How do you operationalize external R&D? September 19, 2012 | BioPharm America™ 2012There is no universally accepted model for externalizing R&D successfully and many key considerations to be weighed in how to create and operationalize these programs. View session here View session here
Emerging markets: Redefining global drug development strategy Emerging markets: Redefining global drug development strategySeptember 19, 2012 | BioPharm America™ 2012Life science firms are rethinking the paradigms of global drug development due to growing market potential outside Western markets in emerging patient populations. View session here View session here
Fierce 15 revealed Fierce 15 revealedSeptember 19, 2012 | BioPharm America™ 2012John Carroll, Editor of FierceBiotech, discusses the current landscape in life sciences with Fierce 15 CEOs. The 2012 Fierce 15 selection was revealed the week of the conference. View session here View session here
New financing models for creative exit strategies New financing models for creative exit strategiesSeptember 19, 2012 | BioPharm America™ 2012Whether constructing new types of licensing deals or rethinking the corporate structure, companies hope to once again make private biotech companies attractive investments. View session here View session here
An exploration of new roles along the drug development value chain: Who’s in, who’s out, and are the new occupants positioned to succeed? An exploration of new roles along the drug development value chain: Who’s in, who’s out, and are the new occupants positioned to succeed?September 19, 2012 | BioPharm America™ 2012New roles are being assumed along the drug development value chain. Who has vacated these roles? Are the new occupants positioned to succeed? View session here View session here
Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD Group, Inc.
Privacy Policy
Terms of Use
BioPharm America EBD Group Massachusetts Biotechnology Council BioPharm America